OpGen (NASDAQ: OPGN) and Caladrius Biosciences (NASDAQ:CLBS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.


This table compares OpGen and Caladrius Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OpGen -585.12% -1,550.02% -253.20%
Caladrius Biosciences -84.10% -180.68% -51.96%

Risk & Volatility

OpGen has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Caladrius Biosciences has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500.

Earnings & Valuation

This table compares OpGen and Caladrius Biosciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
OpGen $3.24 million 4.80 -$18.01 million ($0.78) -0.39
Caladrius Biosciences N/A N/A N/A $1.40 2.56

Caladrius Biosciences has higher revenue, but lower earnings than OpGen. OpGen is trading at a lower price-to-earnings ratio than Caladrius Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for OpGen and Caladrius Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OpGen 0 0 2 0 3.00
Caladrius Biosciences 0 0 2 0 3.00

OpGen currently has a consensus target price of $1.00, suggesting a potential upside of 231.67%. Caladrius Biosciences has a consensus target price of $6.75, suggesting a potential upside of 88.02%. Given OpGen’s higher possible upside, equities research analysts clearly believe OpGen is more favorable than Caladrius Biosciences.

Institutional and Insider Ownership

8.1% of OpGen shares are held by institutional investors. Comparatively, 6.5% of Caladrius Biosciences shares are held by institutional investors. 31.8% of OpGen shares are held by company insiders. Comparatively, 13.1% of Caladrius Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.


Caladrius Biosciences beats OpGen on 5 of the 9 factors compared between the two stocks.

About OpGen

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.